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Background: Hormone receptor (HR) and HER2 expression predict the therapeutic response and prognosis of
breast cancer. In the Middle-East, breast cancer is diagnosed at a young age, and Arabic women are reported to
have a low frequency of HR positive tumors. This study investigates HR and HER2 expression among Kurdish and
Arabic women.
Methods: During 2008–2010, the Sulaimaniyah Directorate of Health records identified 514 Sulaimaniyah Kurdish
women, 227 Kurdish women of other Governates, and 83 Arabic women with a first diagnosis of breast cancer. The
breast cancers of 432 women had immunohistochemistry (IHC) performed for estrogen and progesterone receptors
(ER and PR) and HER2. Age specific and age standardized incidence rates were calculated for Sulaimaniyah Kurds.
Results were compared with Egypt and with United States (US) SEER data.
Results: The median patient age was 46 years and 60.4% were< 50 years old. Tumors of 65.2% of women were ER
+/HER2- with the rate increasing to 78.3% in patients≥ 60 years old in proportions similar to US whites. The total
annual age standardized incidence for breast cancer among Sulaimaniyah Kurds was 40.5/100,000 women, a rate
similar to Egypt but much lower than the US. By HR/HER2 subtype, the highest age specific incidence rates were
16.4 and 45.4/100,000 for ER+/PR+/HER2- tumors in women< 50 or≥ 50 years old, respectively (US whites: 37.7 and
226.1/100,000). Tumors of 20.4% of Sulaimaniyah women were HER2+ with annual incidence rates for ER-/PR-/HER2
+ tumors of women <50 or≥ 50 years old being 4.0 and 6.3/100,000 (US whites: 3.2 and 14.4/100,000). No
significant differences in ER or HER2 status were found between Kurdish and Arabic patients.
Conclusions: Compared to the US, low age standardized and age specific breast cancer incidence rates were
found in Kurdish women; nevertheless, the proportional expression of HR and HER2 for both Kurds and Arabs was
comparable to that of US white women. The great majority of the breast cancer was ER+/HER2- and should
respond to anti-estrogen therapy.
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Estrogen receptor (ER), progesterone receptor (PR), and
HER2 expression of breast cancers vary by patient age,
race, and ethnicity [1-6]. In the United States (US), eth-
nic and racial differences in hormone receptor (HR) sta-
tus have been investigated in large numbers of patients
through the Surveilance Epidemiology and End-Results
(SEER) and Carolinas Breast Cancer Study data bases [1-
8]. On average, African American breast cancer patients
are younger than whites, but even at comparable ages,
tumors are less frequently ER + and the clinical out-
comes for African Americans are demonstrably worse
than for whites [1,4,5,7,9-11].
Breast cancer can be divided into four major subtypes
on the basis of HR and HER2 testing: those that are
HR+ (ER+ and/or PR+) but HER2-, those that are HR+
and HER2+, those that are HR- and HER2+, and those
that are “triple negative” for ER, PR, and HER2 [7,8,10-
12]. HR+/HER2- tumors are the most common subtype
and account for 50% to 80% of breast cancers [1-5].
Patients with ER+/PR + tumors have a more favorable
survival than women with ER-/PR- tumors and the sur-
vival advantage increases substantially with hormonal
therapy [1]. HER2+ tumors comprise 5-25% and triple
negatives 5-15% of breast cancer [7,8,10,13]. Patients
with HER2+ and triple negative tumors tend to be
younger, to have higher grade tumors at higher clinical
stages, and to have shorter survivals [7,8,10,11,13].
The major importance of subtypes is that they deter-
mine the medical treatment patients receive [1,6,12].
ER and PR are strongly predictive of a response to
tamoxifen, and little benefit for tamoxifen can be
shown for HR- negative tumors [12]. The monoclonal
antibody trastuzumab is applicable only for HER2+
tumors and improves survival when administered fol-
lowing anthracyclin-containing protocols that often
contain a taxol [14-19]. For ER + tumors, HER2 over-
expression is associated with lower ER levels and with
tamoxifen resistance [12,16]. Triple negative tumors
tend to be chemosensitive to taxanes, platinums, and
antracyclines but are problematic because of their short
disease free intervals (13).
As in most of the Middle East, breast cancer in Iraq is
the most common documented cancer and is the leading
cause of cancer death among women [20-24]. Studies
from Saudi Arabia and Jordan have reported that Arabic
women have a high proportion of ER- and PR- breast
cancers that occur predominantly under 50 years of age
[23,24]. It is suggested that breast cancer in the Middle-
East may be unusually aggressive, and that the prognosis
for individual patients is unlikely to be favorable [23,24].
While Kurds are ethnically distinct from the Arab
population of Southern Iraq, our preliminary studies
have found that the age specific breast cancer incidencefor Kurdish women was similar to that of Egypt and Jor-
dan [20,21]. The median age of Kurdish patients at diag-
nosis was 46 years, 60% of women were premenopausal,
and nearly 70% of patients had stage 2 or 3 disease [20].
These findings were disquieting but indicated a basic
similarity of breast cancer throughout the region. Stud-
ies on HR and HER2 in the Middle-East are limited, and
the results vary widely [22-27]. Since breast cancer sub-
types are indicators of the choice of and the potential re-
sponse to treatment, this study was undertaken to
determine the age related distribution of the breast can-
cer subtypes among a sizable number of Kurdish and
Arabic women treated at a Northern Iraq reference cen-
ter and to compare the findings with women reported in
the US SEER program.
Methods
The Sulaimaniyah Directorate of Health serves as the
ethics committee for Hewa Hospital and gave permis-
sion for the research. The research was conducted
according to the Helsinki Accords. In 2005, the Direct-
orate of Health established Hewa Hematology and On-
cology Hospital as the central institution for collecting
data on cancer patients and coordinating cancer care in
the region. In the three year period of 2008–2010, 824
women were recorded as having a first diagnosis of
breast cancer. Registry information included age at diag-
nosis, place of residence, and record of histologic con-
firmation of diagnosis.
For the 824 women, 432 had breast biopsies or mast-
ectomy specimens reviewed or analyzed at Shorsh Hos-
pital Pathology Laboratory and immunohistochemical
(IHC) assays were performed. Breast cancer patients at
Hewa Hospital are evaluated and treated by 4 oncology
physicians. There are no treatment guidelines for IHC
testing or for treatment, and the decision to refer speci-
mens for IHC was the choice of the attending physician.
Only two of the four physicians routinely requested spe-
cimen reviews and IHC studies.
Histological sections were cut at 4 μ and stained with
hematoxylin and eosin (H&E) stains and additional sec-
tions were affixed to charged slides for IHC. The breast
cancers were classified by histologic type and given a
Nottingham combined histologic grade. Slides for IHC
were stained for ER, PR, and HER2 using antibodies,
buffers and linking systems purchased from Dako™
(Dako, Denmark). ER used clone SP1, PR clone PgR 636,
and HER2 polyclonal rabbit anti-human c-erbB-2. Proce-
dures were performed with 15 minutes pressure cooker
heat induced epitope retrieval in pH 9.0 TRIS target re-
trieval solution (TRS) for ER and pH 7.0 citrate TRS for
PR and HER2. The linking/amplification system con-
sisted of EnVision™ Systems polymer-enzyme conjugate
(Dako, Denmark).
Table 1 Summary of characteristics of women with breast
cancer having and not having immunohistochemistry
(IHC) assays performed, Sulaimaniyah, Iraq (2008–2010)





No. % No. %
Patients (total = 824) 392 47.6 432 52.4
Age
20-49 216 55.1 261 60.4 0.26
50-59 100 25.5 102 23.6
≥ 60 76 19.4 69 16.0
Mean (range) 49.5 ± 12.0 (23–88) 47.8 ± 11.5 (21–83) 0.03
Ethnicity/residence
Kurd/Sulaimaniyah 241 61.4 265 61.3 0.12
Kurd/not-Sulaimaniyah 91 23.2 117 27.1
Arab/not-Sulaimaniyah 63 16.0 50 11.6
Tumor stage
1 36 9.2 37 8.6 0.97
2 121 30.9 136 31.5
3 104 26.5 115 26.6
4 28 7.1 28 6.5
Unknown 103 26.3 116 26.9
* Comparing the distribution of IHC tested and non-tested patients by age,
ethnicity/residence, and tumor stage (X2 tests). The difference in the ages of
IHC tested and non-tested subjects was compared by a K-S test for normality
and equal distribution and a t-test.
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quantitatively using the “Allred” 0 to 8 scoring system
that adds scores for signal intensity (0, none; 1, weak; 2,
moderate; 3, strong) and the proportion of positive
tumor cell nuclei (0, none; 1< 1%; 2, 1-10%; 3, 11-33%;
4, 34-66%; 5, 67-100%). Scores ≥ 3 were considered
positive. HER2 was graded as 0 to 3+ with 3+ having
strong complete membrane staining around> 30% of
tumor cells. Scores of 3+ were considered over-
expressed or positive and scores ≤ 2+ as negative. Fluor-
escence in-situ hybridization for HER2 amplification
was not performed.
For Sulaimaniyah residents, annual age specific inci-
dence rates per 100,000 women were calculated on the
basis of the 2002 World Health Organization (WHO)
census estimates for Sulaimaniyah Governate. An age
standardized incidence rate was calculated for the
Sulaimaniyah population using the WHO population
distribution ratio. An age standardized incidence rate
for Egypt was obtained from the monograph of the
NIH sponsored Middle-East Cancer Consortium [21].
Incidence estimates for Sulaimaniyah and Egypt were
compared with US SEER data from Atlanta, Georgia
for women diagnosed with breast cancer in 2003–2004
as tabulated by Lund et al. [7]. The source of the
population of white and African American women at
risk by age for the two county Atlanta area was the
2000 US Census. For triple subtypes, age specific inci-
dence rates for Sulaimaniyah residents< 50 and ≥ 50
years old was calculated using the one year average of
each subtype multiplied by a factor of 1.91 to account
for the 47.6% of patients who did not have IHC
testing.
Data was entered into an Excel worksheet and analyzed
with Stata™ (Stata Corp, College Station, TX) statistical
software. The proportional distribution of patients
among different groups was analyzed by Chi square tests.
Comparisons of age among the three population groups
used Dunn’s analysis of variance on ranks. Logistic re-
gression was used to evaluate the relationships between
HER2 status as the dependent variable and age, tumor
grade, and ER status as independent variables. For all
statistical procedures P< 0.5 was considered significant.
Results
General characteristics of the patient population
During 2008–2010, 824 new breast cancer patients were
registered at Hewa Hospital (Table 1). IHC studies were
performed on 432 (52.4%) patients. The average age at
diagnosis for all patients was 47.8 ± 11.5 years with a
range of 21 to 83 and a median of 46 years. Patients not
having IHC were slightly older than those on whom IHC
was performed, P = 0.03. For all patients, 514 were Kurd-
ish residents of the Sulaimaniyah Governate, 227 wereKurdish from Erbil, Dohuk, or Germyan, and 83 were
Arabs from outside of Sulaimaniyah. For the patients
having IHC studies, 265 were Kurdish residents of Sulai-
maniyah, 117 Kurdish women residing outside of the
Sulaimaniyah Directorate, and 50 were Arab non-
residents of Sulaimaniyah.
No significant differences were seen by ethnicity and
residence or tumor stage among patients with or without
IHC. For patients having IHC studies, the diagnoses were
invasive ductal carcinoma NOS in 401 cases (92.8%), in-
vasive lobular carcinoma in 17 cases (3.9%), ductal car-
cinoma in-situ in 6 cases (3.9%), metaplastic carcinoma
in 2 cases, secretory carcinoma in 2 cases, mucinous car-
cinoma in 2 cases, and tubular and invasive papillary car-
cinoma in one case each. All invasive lobular carcinomas
were ER + and HER2-; 15 were PR+ and two PR-.
Comparisons of Kurdish and Arab women
By ethnicity and region, the average age of patients was
not significantly different (Table 2). In all groups, the
great majority of patients were< 50 years old. Most
patients were found at stage 2 or stage 3 of their disease.
This varied from 56.3% to 55.6% for the two Kurdish
groups to 74% for Arabs. For all patients, only 11.7%
were diagnosed with stage 1 tumors. Histologic grade
Table 2 Characteristics of women with breast cancers having immunohistochemistry studies performed and the







No. % No. % No. %
Age 0.56
20-49 155 58.5 76 65.0 30 60.0
50-59 67 25.3 25 21.4 10 20.0
≥60 43 16.2 16 13.7 10 20.0
Mean age± SD 48.7 ± 11.1 46.4 ± 12.3 46.1 ± 11.7 0.12
Stage 0.30
1 24 9.1 12 10.3 1 2.0
2 86 32.5 33 28.2 17 34.0
3 63 23.8 32 27.4 20 40.0
4 18 6.8 7 6.0 3 6.0
Unknown 74 27.9 33 28.2 9 18.0
Tumor grade 0.86
I 26 9.1 12 10.3 6 12.0
II 116 43.8 57 48.7 22 44.0
III 100 33.7 41 35.0 20 40.0
Not assigned 23 27.9 7 6.0 2 4.0
ER, PR and HER2 0.98
ER + 194 73.2 89 76.1 39 78.0
PR + 170 64.2 80 68.4 36 72.0
HER2 + 54 20.4 29 24.8 11 22.0
ER/PR status 0.94
ER+/PR+ 163 61.5 76 65.0 35 70.0
ER+/PR- 31 11.7 13 11.1 4 8.0
ER-/PR+ 8 3.0 4 3.4 1 2.0
ER-/PR- 63 23.8 24 20.5 10 20.0
ER/HER2 status 0.71
ER+/HER2- 170 64.9 74 63.8 35 70.0
ER+/HER2+ 22 8.4 15 12.9 4 8.0
ER-/HER2- 38 14.5 13 11.2 4 8.0
ER-/HER2+ 32 12.2 14 12.1 7 14.0
Triple negative 33 12.6 10 8.6 4 8.0
* Comparing the distribution of patients in ethnicity/residence groups by age, tumor stage, tumor grade, and ER, PR, and HER2 status (X2 tests). The difference in
ages of the ethnicity/residence groups were compared by Dunn’s analysis of variance on ranks.
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hormone receptors and HER2 was performed on lymph
node metastases or fine needle aspirations and a grade
for the primary tumor was not assigned.
The proportion of ER+ tumors varied from 73.2% to
78.0% and HER2 over-expression from 20.6% to 22%
with differences not being significant, P = 0.98. By
population group, 61-70% of tumors were ER+/PR+ and
8–11.7% were ER+/PR-. ER-/PR + tumors were found inonly 2.0-3.4% of patients. The proportion of cases sub-
classified by ER and HER2 status and the proportion of
"triple negative" tumors was similarly distributed among
the ethnic/residence groups.
Hormone receptors and HER2 by patient age, tumor
stage, and tumor grade
ER/HER2 status succinctly summarizes HR and HER2
combinations (Table 3). There are eight possible ER,
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ing IHC studies, there were 48 ER+/PR- tumors
(11.1%) and 13 ER-/PR + tumors (3.0%) represented in
these combinations. The categories of ER+/HER2- and
ER+/HER2+ tumors captures the former and omits
only the 3% of tumors represented by the latter. This
allows the strongest data analysis with the fewest cat-
egories of HR and HER2. For the analyses of ER/
HER2 combinations with age, stage and grade, data
from all ethnic/residence groups are combined. Data
was initially tabulated in the ten year age ranges 20–
39, 40–49, 50–59, 60–69, and 70+. No differences
were seen between the ages 20–49 or in age groups
over 59, and the data was consolidated into three
groups 20–49, 50–59, and 60 or more years old.
HR and HER2 expression tended to change with age.
The largest category of tumors was ER+/HER2-, and
the proportion of patients with ER+/HER2- tumors
increased from 59.9% at 20–49 years to 69.6% at 50–
59 and 78.3% at ≥ 60 years of age. Although HER2+
tumors tended to be nearly equally distributed between
ER+ and ER- tumors, HER2- tumors were predomin-
antly found in those that were ER+. The proportion of
patients with HER2+ tumors was 26.1% at 20–49 years
of age and 14.4% at ≥ 60 years of age. Because of the
relatively few patients≥ 60 years old, these age differ-
ences tended toward but did not achieve significance,
P = 0.12.
No relationship was found between ER/HER2 status
and tumor stage, but by tumor grade, ER+/HER2-
tumors were predominantly found in pathologic grades ITable 3 Estrogen receptor (ER) and HER2 status in breast can







No. % No. % No.
age
20-49 154 59.9 31 12.1 36
50-59 71 69.6 5 4.9 14
≥ 60 54 78.3 5 7.2 5
Stage
1 24 64.9 5 13.5 6
2 92 68.1 10 7.4 17
3 73 63.5 12 10.4 13
4 16 57.1 5 17.9 5
Grade
I 43 97.7 0 0 1
II 157 80.9 12 6.2 11
III 65 40.6 22 13.8 38
* Comparing the distribution of ER/HER2 status and triple negative tumors by patie
Tumor characteristics are compared by age, tumor stage, and tumor grade.or II; while, HER2+ and ER-/HER2- as well as triple
negative tumors were predominantly grade III. In logistic
regression with HER2 status as the dependent variable
and age at diagnosis, ER status, and tumor grade as in-
dependent variables, HER2 was significantly related to
a negative ER status (P< 0.001) and higher tumor grade
(P< 0.001) but not to age (P = 0.48).Breast cancer incidence and HR/HER2 combinations in the
Kurdish population of sulaimaniyah. A comparison with
Egypt and US SEER data
For the 514 patients who were Sulaimaniyah residents,
the age standardized incidence of breast cancer was 40.5
per 100,000 women (Table 4). The age specific incidence
rate began to peak at 40–44 years of age and remained
somewhat stable until age 60 when it started to decline.
At age 70–74, the rate was similar to that of 35 to
39 year olds; while, at 75 years of age and above, the
rates were one-half those seen among 30–34 year old
women.
The average age of Sulaimaniyah residents was similar
to Egyptians but was 12 years younger than US whites
and 8 years younger than African Americans. Nearly 60%
of Sulaimaniyah residents were under 50 years old com-
pared to just 21.7% and 31.7% for the two US groups.
Despite the younger age, 73.2% of Sulaimaniyah women
had ER+ tumors compared to 81.1% of US whites. ER +
rates for Egyptians and African Americans were similar
at 65.0 and 65.5%, respectively. Tumors were HER2+ for







% No. % No. %
0.12
14.0 36 14.0 30 11.7
13.7 12 11.8 12 11.8
7.2 5 7.2 5 7.2
0.81
16.2 2 5.4 4 10.8
12.6 16 11.9 13 9.6
11.3 17 14.8 13 11.3
17.9 2 7.1 4 14.3
<0.001
2.3 0 0 1 2.3
5.7 14 7.2 8 4.1
23.8 35 21.9 33 20.6
nt age, tumor stage, and tumor grade (X2 tests).












0-4 0 0 112,952 0 8.86 0
5-9 0 0 101,995 0 8.69 0
10-14 0 0 115,164 0 8.60 0
15-19 0 0 105,537 0 8.47 0
20-24 2 0.7 82,206 0.9 8.22 0.1
25-29 10 3.3 80,746 4.1 7.93 0.3
30-34 29 9.7 62,706 15.5 7.61 1.2
35-39 66 22.0 37,634 58.5 7.15 4.2
40-44 99 33.0 26,768 123.3 6.59 8.1
45-49 80 26.7 23,502 113.6 6.04 6.9
50-54 66 22.0 20,256 109.1 5.37 5.9
55-59 60 20.0 15,200 131.6 4.55 6.0
60-64 35 11.7 14,197 82.4 3.72 3.1
65-69 31 10.3 12,123 85.0 2.96 2.5
70-74 21 7.0 12,419 56.4 2.21 1.3
75-79 6 2.0 5,607 35.7 1.52 0.5
80+ 9 3.0 10,363 28.9 1.55 0.4
Total 514 100.00 40.5
Age adjusted incidence rates are calculated using the World Health Organization (WHO) adjustment ratio.
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African American women, respectively.
The triple subtypes as provided in Table 5 were chosen
for a comparison of HR and HER2 combinations, be-
cause results for these subtypes were recently published
by Lund et al. [7] from a US SEER based analysis of
American women in Atlanta, Georgia. The distribution
of the subtypes was similar in Kurdish, US white, and Af-
rican Americans except for two categories. The most
common ER+/PR+/HER2- subtype occurred in a much
higher proportion of US whites than either Kurds or
African Americans. In contrast, the triple negative
ER-/PR-/HER2-subtype was found in 26.8% of African
Americans, twice the rate of 12.4% observed for both
Kurds and US whites.
Compared to Sulaimaniyah residents, the age standar-
dized incidence of breast cancer was slightly higher in
Egyptians but was three times higher in African Ameri-
cans and nearly four times higher in US whites. For the
major ER+/PR+/HER2- subtype, the incidence for Kurd-
ish patients< 50 years old was relatively low, although
still higher than any other subtype. For patients≥ 50 years
old, the incidence of ER+/PR+/HER2- tumors increased
3-fold in Kurds and 6-fold in US whites and African
Americans. ER+/PR+/HER2+ and ER-/PR-/HER2+
tumors had the lowest incidence rates of the triplesubtypes in all three populations with the lowest rates
being found in Kurds. The HER2 + rates changed little or
increased only moderately in older patients. Triple negative
tumors had the highest incidence rates after ER+/PR
+/HER2- tumors in all three groups with 2.6 to 4-times
higher incidences in patients ≥ 50 compared to those
< 50 years old. The incidence of triple negative tumors
was highest for African Americans. For Kurds, it was
less than half that of US whites.
Discussion
The study shows that Kurdish women of Sulaimaniyah
have a relatively low incidence of breast cancer, but
that the cancers are diagnosed at advanced stages and
at an average age that is 8 to 12 years younger than
women in the US. It is further shown that, at equiva-
lent ages, the breast cancers of both Kurdish and
Arabic women have HR profiles similar to that of US
white women.
The young average age of breast cancer patients in the
Middle-East is not the result of an increase in breast
cancer in young people but because of the relatively low
incidence in older women [20-22]. Egypt is thought to
have the highest rate of breast cancer in the Middle-East
with an age standardized incidence of 53.9/100,000 [21].
For Kurdish women, the age standardized incidence is
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being less than half the rate of 116.0/100,000 seen in the
US white women [20,21]. For Egyptian and Kurdish
women, the age specific incidences for patients< 50 are
similar or somewhat less than in the US and peak at 50–
59 years of age [20,21]. These patterns contrasts markedly
with the West where breast cancer steadily increases in
postmenopausal women and at age 70 doubles the rates
seen at 50–54 years old [9,21].
The most comprehensive studies on breast cancer HR
and HER2 status in the Middle-East come from Egypt,
Saudi Arabia and Jordan [22-27]. The reports emphasizeTable 5 Comparisons of Sulaimaniyah Kurdish breast cancer p
American women by age, hormone receptor (HR) and HER2 s
rates
Sulaimaniyah Egypt
Characteristics No. % No.
Patients 265 203a
Age Mean 48.7 ± 11.1 51.3 ± 10.8
<50 155 58.5 92/172
≥50 110 41.5 80/172
HR and HER2
ER+ 194 73.2 132
PR+ 170 64.2 89
HER2+ 54 20.4 51
Triple subtypes
ER+/PR+/HER2- 145 54.7 -
ER+/PR+/HER2+ 15 5.7 -
ER-/PR-/HER2+ 29 10.9 -
ER-/PR-/HER- 33 12.4 23
Incidence b,c













a The Egyptian patients include 5 males.
b Total incidence consists of age standardized incidence rates per 100,000 women
c For triple subtypes, annual incidence rates per 100,000 women are age adjusted f
by specific subtypes are multiplied by a factor of 1.91 on the assumption that unte
d The age standardized incidence of breast cancer among Egyptian women was ob
The data for US whites and African Americans was from Atlanta, Georgia for the yethe young age at diagnosis with most patients being be-
tween 40–50 years old. Outside of Egypt, the proportion
of ER+ cases ranges from a low of 19.9% in Saudi Arabia
to 52.8% in Jordan [23,24].
An analysis of ER testing at the Gharbiah, Egypt Can-
cer Registry for the years 2001–2006 [22] identified
3673 breast cancer patients having a median age of
50.1 with urban women at 51.8 years being slightly
older than those from rural areas at 49.2 years. It was
notable that a majority of the patients (62.9%) had an
unknown ER status. For rural women, the ratio of ER +
to ER- tumors showed only a slight excess of ER +atients with Egyptian and with US white and African
tatus, and age standardized and age specific incidence
US white African Amer.
% No. % No. %
967 814
61.2 ± 14.6 56.9 ± 13.4
53.5 210 21.7 258 31.7
46.5 767 78.3 556 68.3
65.0 732/903 81.1 506/773 65.5
43.8 636/901 70.6 426/771 55.3
25.1 108/821 13.2 110/689 16.0
- 605/814 74.3 394/687 57.4
- 67/” 8.2 60/” 8.7
- 41/” 5.0 49/” 7.1










using the WHO adjustment ratio.
or their respective populations. For Sulaimaniyah, the breast cancers identified
sted patients will have the same HR/HER2 expression ratios as tested patients.
tained from 1999–2001 data presented at the MECC [21].
ars 2003–2004 obtained through US SEER [7].
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similar to US white women and our Kurdish and
Arabic patients. These findings have been supported by
a more recent Egyptian study by Salhia et al. [28] and
suggest that for urban Egyptian women, and by infer-
ence patients treated in Sulaimaniyah, the predominant
mode of tumor development is related to estrogenic
risk factors and that most tumors will be tamoxifen
responsive.
The relatively high ER+ rates do not mean that there
is a correspondingly reduced burden of morbidity and
mortality for Kurdish and Arabic breast cancer patients.
In Western studies, the tumors of young patients tend
to be of higher histologic grade and to have higher
growth fractions than the tumors of older patients with
these factors being independent of HR expression
[8,29,30]. Among Sulaimaniyah patients, 57.8% of ER +
tumors were found in patients< 50 years old and 12.8%
were ER+/HER2+. The former, on the basis of patient
age, are potentially aggressive tumors and the latter, on
the basis of ER and HER2 co-expression, may be tamoxi-
fen resistant [12,16].
The proportion of HER2+ tumors among Kurds and
Arabs at 20.4% to 24.8% reflects the prevalence of high
histologic grade cancers. The 21.9% of grade III tumors
that were ER-/HER2+ and the 13.8% that were ER
+/HER2+ are rates comparable to those seen in high
grade tumors in the US and Europe [7,8,11,30]. Al-
though, the proportions of HER2+ tumors among Kurds
were higher than for US whites, the incidence of HER2+
tumors, was lower than for either US whites or African
Americans.
It is the marked increase in ER+/PR+/HER2- tumors
among older women that characterizes US and European
populations [7]. For Sulaimaniyah Kurds, ER+/PR+/
HER2- tumors are the most common triple subtype and
have an incidence of 16.4/100,000 under 50 that increases
to 45.5/100,000 among patients≥ 50 years old. This con-
trasts with the much higher rate of 226.1/100,000 among
post-menopausal US whites [7].
A Finnish study showed that over a 22 year period
when the incidence of ER + tumors doubled from 44.1
to 82.3/100,000, the proportion of HER2+ tumors
declined from 21.6% to 13.6% [31]. During this time,
the incidence of HER2+ tumors remained stable at 12
to 13/100,000. The higher proportion but relatively
low incidence of HER2+ tumors in Kurdish women
appears to correspond to the Finnish data and does
not indicate an increased risk of developing HER2+
breast cancers in younger women but rather a low risk
of developing favorable ER+/HER2- tumors after the
menopause.
Triple negative tumors that do not fall into a defined
hormonal or HER2 treatment category were found in11% of Sulaimaniyah residents and were the second
most common triple subtype. This proportional rate is
not excessive, and the estimated incidences of triple
negative tumors for both younger and older Kurdish
women were somewhat lower than US whites and con-
siderably lower than the very high incidence among Afri-
can Americans [7].
The general similarity of tumor characteristics to those
of US white women suggests that breast cancer in the
Middle-East resembles the Western disease and that the
principles of treatment in Western medical practice may
produce results comparable to the US. Improved results
may be difficult to achieve in the near term. A very large
proportion of Gharbiah and Sulaimaniyah patients had
untested tumors and were not being provided the benefit
of therapy relevant to HR or HER2 status [22,32].
In Sulaimaniyah, the failure to test was the choice of
the physicians managing the patients. The Sulaimaniyah
Governate supports pharmaceutical services that provide
nearly all currently recommended generic drugs for
breast cancer management including trastuzumab.
Nevertheless, many breast cancer patients continue to
be treated with surgery alone until there are recurrences
or metastases. The Breast Health Global Initiative
defines testing for ER status as a “basic level” of path-
ology evaluation for breast cancer in low and middle in-
come countries [32,33]. The lack of studies for HR and
HER2 in nearly 50% of Sulaimaniyah patients points to
deficiencies in regional practice standards that appear to
be common in many lower income countries but that
should be remediable with suitably directed educational
programs.
Conclusions
The average age of breast cancer patients in Sulaima-
niyah was 8 to 12 years younger than their US counter-
parts, and most patients were diagnosed at an advanced
stage of their disease. Nevertheless, the frequency of the
expression of ER, PR, and HER2 in breast cancers of
both Kurdish and Arabic women was similar to US
white women of similar age and with similar grade
tumors. The findings suggest that the administration of
anti-estrogenic and chemotherapy regimens appropriate
for tumor HR and HER2 status could produce survivals
comparable to those seen for US white women.
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